4.5 Review

Physiology and pathophysiology of the calcium-sensing receptor in the kidney

Journal

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
Volume 298, Issue 3, Pages F485-F499

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajprenal.00608.2009

Keywords

proximal tubule; thick ascending limb; distal convoluted tubule; collecting duct; 1,25-dihydroxyvitamin D-3; parathyroid hormone; hypercalcemia; hypocalcemia; hypercalciuria; calcimimetic; hyperparathyroidism; inactivating mutation; activating mutation; polymorphism; familial hypocalciuric hypercalcemia; neonatal severe primary hyperparathyroidism; autosomal dominant hypoparathyroidism

Funding

  1. Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D01591X]
  2. National Institute of Diabetes and Digestive and Kidney Diseases [DK-078331]
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078331] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 298: F485-F499, 2010. First published November 18, 2009; doi:10.1152/ajprenal.00608.2009.-The extracellular calcium-sensing receptor (CaSR) plays a major role in the maintenance of a physiological serum ionized calcium (Ca2+) concentration by regulating the circulating levels of parathyroid hormone. It was molecularly identified in 1993 by Brown et al. in the laboratory of Dr. Steven Hebert with an expression cloning strategy. Subsequent studies have demonstrated that the CaSR is highly expressed in the kidney, where it is capable of integrating signals deriving from the tubular fluid and/or the interstitial plasma. Additional studies elucidating inherited and acquired mutations in the CaSR gene, the existence of activating and inactivating autoantibodies, and genetic polymorphisms of the CaSR have greatly enhanced our understanding of the role of the CaSR in mineral ion metabolism. Allosteric modulators of the CaSR are the first drugs in their class to become available for clinical use and have been shown to treat successfully hyperparathyroidism secondary to advanced renal failure. In addition, preclinical and clinical studies suggest the possibility of using such compounds in various forms of hypercalcemic hyperparathyroidism, such as primary and lithium-induced hyperparathyroidism and that occurring after renal transplantation. This review addresses the role of the CaSR in kidney physiology and pathophysiology as well as current and in-thepipeline treatments utilizing CaSR-based therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available